Weight lifted for Arena: Eisai launches Belviq
This article was originally published in Scrip
The first new competitor for the Vivus weight loss therapy Qsymia (topiramate and phentermine) will hit the market on 11 June when the Arena Pharmaceuticals and Eisai drug Belviq (lorcaserin) will be available in US pharmacies.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.